Log in Register
Menu
Search
Monoclonal Antibodies

Anti-HLA-A2 [BB7.2]

  • Datasheet
  • Reviews (0)
Print

Info

Review this reagent
Catalogue Number 151297
Applications FACS IHC IF Fn
Antigen/Gene or Protein Targets Human Leukocyte Antigen- A2
Reactivity Human
Relevance Human Leukocyte Antigens (HLA) are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). This antibody can be used for HLA typing.
Host Mouse
Immunogen Papain solubilised HLA-A2,
Subclass IgG2b
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes BB7.2 fixes complement and is cytotoxic for peripheral blood leukocytes and lymphoid cell lines.

Chawla et al., 2016 - BB7.2 blocked the HLAA2/T cell receptor interactions and specifically killied target cells by E75-CTL.
Research Area Immunology
Adapted from Lasso et al. 2016. PLoS One. 11(3):e0150996. PMID: 26974162. Fig. Flow cytometry gating strategy and frequency of TcTLE-specific CD8+ T cells. Dot plots representative of the analysis of an HLA-A2-negative chagasic patient. (A) Lymphocytes were selected, and cell doublets were excluded from the analysis for the identification of CD8+ T cells based on the forward scatter area (FSC-A) and forward scatter height (FSC-H) (singlet 1), forward scatter width (FSC-W) and forward scatter height (FSC-H) (singlet 2), and side scatter width (SSC-W) and SSC-H characteristics (singlet 3). Finally, live CD3+ CD8+ cells were selected. (B) Selection of TcTLE peptide-specific CD8+ T cells by soluble tetramer assay. (C) Frequency of TcTLE peptide-specific CD8+ T cells from 20 HLA-A2-negative chronic chagasic patients. The cut-off point, which was fixed at 0.063, is indicated by the dotted line.
Add an image

References: 22 entries

Huang et al. 2016 Scientific Reports.

FACS

View  

Gunasekaran et al. 2016. Am J Transplant. :. PMID: 27278097.

View  

Reches et al. 2016. J Immunol. :. PMID: 27194785.

FACS

View  

Chawla et al. 2016. Cancer Immunol Immunother. :. PMID: 27129972.

Fn

View  

Srivastava et al. 2016. J Virol. 90(8):3913-28. PMID: 26842468.

View  

Nayak et al. 2016. Am J Transplant. :. PMID: 27062199.

View  

MacDonald et al. 2016. J Clin Invest. 126(4):1413-24. PMID: 26999600.

View  

Lasso et al. 2016. PLoS One. 11(3):e0150996. PMID: 26974162.

FACS

View  

Lasso et al. 2016. Peptides. 78:68-76. PMID: 26854383.

View  

Srivastava et al. 2016. J Virol. :. PMID: 26842468.

FACS

View  

Ma et al. 2016. J Immunol. :. PMID: 26792804.

FACS

View  

Mahiti et al. 2016. MBio. 7(1):. PMID: 26787826.

FACS

View  

Horiuchi et al. 2015. Oncol Rep. :. PMID: 26398429.

IHC IF

View  

Dellgren et al. 2015. PLoS One. 10(8):e0135385. PMID: 26258424.

View  

Rancan et al. 2015. PLoS Pathog. 11(6):e1004906. PMID: 26067064.

FACS

View  

Egui et al. 2015. PLoS One. 10(3):e0122115. PMID: 25816096.

View  

Khan et al. 2015. J Virol. :. PMID: 25878105.

View  

Noy et al. 2015. Mol Cancer Ther. :. PMID: 25852061.

View  

Cheent et al. 2013. Proc Natl Acad Sci U S A. 110(42):16981-6. PMID: 24082146.

View  

Whitfield-Larry et al. 2011. Diabetes. 60(6):1726-33. PMID: 21521873.

View  

Parham et al. 1981. Hum Immunol. 3(4):277-99. PMID: 7035415.

View  

Brodsky et al. 1979. Immunol Rev. 47:3-61. PMID: 95015.

View  

Add a reference

    Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.

    Review this reagent


This reagent does not have any reviews at the moment.